What is HRGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HRGN?

P/E (TTM) is n/a and 52-week range is $0.96 to $2.46 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HRGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HRGN?

The company profile lists revenue (TTM) near $983K, net income (TTM) near $-669M, EPS (TTM) near $-0.39 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Harvard Apparatus Regenerative Technology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Holliston, Massachusetts, US, 17.6M shares outstanding, ISIN US09074M2026 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Harvard Apparatus Regenerative Technology Inc

$HRGN

Health Care · Biotechnology

IR Run Scenarios

$2.30

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2013-10-14. The firm's technology is based on its cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The firm is advancing its Cellspan esophageal implant product candidate through an Investigator-Initiated Trial targeting pediatric patients with Esophageal Atresia. Its biocompatible scaffold component of its esophageal implant is constructed primarily of thin polyurethane fibers. Its other product candidates in development pipeline are targeted at the reconstruction of the colon and uterus wound repair. The Company, through its subsidiary, Harvard Apparatus Regenerative Technology Limited, is focused on personal healthcare, including dietary supplements.

Employees

Website

hregen.com/

IPO

2013-10-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)